Epilepsy Therapeutics Market in the APAC Region 2015-2019

アジア太平洋のてんかん(Epilepsy)治療薬市場

◆タイトル:Epilepsy Therapeutics Market in the APAC Region 2015-2019
◆商品コード:IRTNTR4895
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年12月31日
◆ページ数:86
◆資料形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:アジア太平洋
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥280,000見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥313,600見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD3,500 ⇒換算¥392,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、アジア太平洋のてんかん(Epilepsy)治療薬市場について調査・分析し、エグゼクティブサマリー、市場概観、業界の構造分析、アジア太平洋のてんかん(Epilepsy)治療薬市場規模及び予測、市場シェア、主要国別分析、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Epilepsy Therapeutics
Epilepsy is a spectrum of brain disorders varying from benign to severe, disabling, and life-threatening symptoms. It is caused by various factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and birth trauma. However, when the underlying cause of the disease is unidentified, as in the majority of the cases, it is known as idiopathic epilepsy. Epilepsy is characterized by repeated occurrence of generalized or focal seizures. An imbalance between the inhibitory and excitatory signals of the brain, leading to a sudden onset of excitation, results in seizures. Occurrence of two or more unprovoked seizures is an important criterion to diagnose a person as being epileptic.

TechNavio’s analysts forecast the Epilepsy Therapeutics market in the APAC to grow at a CAGR of 5.78 percent over the period 2014-2019.

[Covered in this Report]
This report covers the present scenario and the growth prospects of the Epilepsy Therapeutics market in the APAC for the period 2015-2019. To calculate the market size, the report considers the revenue generated through the sales of anti-epileptic drugs used for the treatment of the symptoms of epilepsy in APAC.
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market in the region. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio’s report, Epilepsy Therapeutics Market in the APAC 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the APAC regions; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key Countries]
• Australia
• China
• India
• Japan

[Key Vendors]
• Eisai
• GlaxoSmithKline
• Pfizer
• UCB

[Other Prominent Vendors]
• Abbvie
• Acorda Therapeutics
• Dainippon Sumitomo Pharma
• F. Hoffmann-La Roche
• H. Lundbeck
• Janssen Pharmaceuticals
• Marinus Pharmaceuticals
• Meda AB
• Novartis
• Sage Therapeutics
• Shire
• Sunovion Pharmaceuticals
• Supernus Pharmaceuticals
• Upsher-Smith Laboratories
• Valeant Pharmaceuticals

[Market Driver]
• Unmet Medical Need
• For a full, detailed list, view our report

[Market Challenge]
• Generic Erosion
• For a full, detailed list, view our report

[Market Trend]
• Reformulation of Marketed Drugs
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

01. Executive Summary

02.List of Abbreviations

03.Scope of the Report
03.1 Market Overview
03.2 Product Offerings

04.Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology

05.Introduction

06.Incidence and Prevalence
06.1 Global
06.2 China
06.3 Japan

07.NIH Funding for Epilepsy

08.Market Landscape
08.1 Market Overview
08.2 Market Size and Forecast
08.3 Five Forces Analysis

09.Market Segmentation by Generation of Drugs

10.Country-wise Segmentation
10.1 Country-wise YoY Growth Rate of Epilepsy Therapeutics market in APAC 2014-2019
10.2 Epilepsy Market in Japan
10.3 Epilepsy Market in Australia
10.4 Epilepsy Market in China
10.5 Epilepsy Market in India

11.Key Leading Countries
11.1 Japan
11.2 Australia
11.3 China
11.4 India

12.Buying Criteria

13.Market Growth Drivers

14.Drivers and their Impact

15.Market Challenges

16.Impact of Drivers and Challenges

17.Market Trends

18.Trends and their Impact

19.Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 GlaxoSmithKline
19.2.2 Eisai
19.2.3 UCB
19.2.4 Pfizer
19.3 Other and Future Prominent Vendors

20.Key Vendor Analysis
20.1 Eisai
20.1.1 Key Facts
20.1.2 Business Overview
20.1.3 Product Segmentation by Revenue 2013
20.1.4 Product Segmentation by Revenue 2012 and 2013
20.1.5 Geographical Segmentation by Revenue 2013
20.1.6 Business Strategy
20.1.7 Recent Developments
20.1.8 SWOT Analysis
20.2 GlaxoSmithKline
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Business Segmentation
20.2.4 Business Segmentation by Revenue 2012 and 2013
20.2.5 Sales by Geography
20.2.6 Pipeline Products
20.2.7 Business Strategy
20.2.8 Key Information
20.2.9 SWOT Analysis
20.3 Pfizer
20.3.1 Key Facts
20.3.2 Business Overview
20.3.3 Business Segmentation by Revenue 2013
20.3.4 Business Segmentation by Revenue 2012 and 2013
20.3.5 Geographical Segmentation by Revenue
20.3.6 Business Strategy
20.3.7 Key Developments
20.3.8 SWOT Analysis
20.4 UCB
20.4.1 Key Facts
20.4.2 Business Overview
20.4.3 Product Segmentation by Revenue 2013
20.4.4 Product Segmentation by Revenue 2012 and 2013
20.4.5 Geographical Segmentation by Revenue 2013
20.4.6 Business Strategy
20.4.7 Recent Developments
20.4.8 SWOT Analysis

21.Other Reports in this Series

[List of Exhibits]
Exhibit 1: Market Research Methodology
Exhibit 2: Incidence and Prevalence of Epilepsy by WHO
Exhibit 3: Treatment Statistics for Epilepsy
Exhibit 4: Prevalence of Epilepsy in China
Exhibit 5: NIH Funding for Epilepsy (US$ million) FY2011-FY2015
Exhibit 6: Epilepsy Therapeutics market in APAC 2014-2019 (US$ million)
Exhibit 7: Epilepsy Therapeutics Market in APAC Segmentation by Generation of Drugs
Exhibit 8: Market Share of APAC in Global Epilepsy Market
Exhibit 9: Epilepsy Therapeutics Market in APAC by Country 2014
Exhibit 10: Epilepsy Therapeutics market in APAC by Country 2019
Exhibit 11: Epilepsy Therapeutics Market in APAC 2014-2019 (US$ million)
Exhibit 12: Epilepsy Therapeutics Market in APAC 2014-2019
Exhibit 13: Epilepsy Market in Japan 2014-2019 (US$ million)
Exhibit 14: Epilepsy Market in Australia 2014-2019 (US$ million)
Exhibit 15: Epilepsy Market in China 2014-2019 (US$ million)
Exhibit 16: Epilepsy Market in India 2014-2019 (US$ million)
Exhibit 17: Key Leading Countries in the Epilepsy Therapeutics market in APAC 2014
Exhibit 18: Impact of Loss of Exclusivity for Lyrica in Canadian market (US$ million)
Exhibit 19: GlaxoSmithKline: Anti-epileptic Drug Portfolio in APAC
Exhibit 20: Lamictal Revenue 2011-2014 (US$ million)
Exhibit 21: Lamictal Sales Segmentation by Geography 2014
Exhibit 22: Eisai: Anti-epileptic Drug Portfolio in APAC
Exhibit 23: Fycompa: Pipeline Status
Exhibit 24: Inovelon: Pipeline Status
Exhibit 25: UCB: Anti-epileptic Drug Portfolio in APAC
Exhibit 26: Keppra Sales 2010-2014 (US$ million)
Exhibit 27: Keppra Sales by Geography 2014
Exhibit 28: Vimpat Sales by 2009-2014 (US$ million)
Exhibit 29: Vimpat Sales by Geography 2014
Exhibit 30: Vimpat: Pipeline Status
Exhibit 31: Lyrica Revenue 2011-2014 (US$ million)
Exhibit 32: Lyrica Revenue by Geography 2014
Exhibit 33: Eisai: Product Segmentation by Revenue 2014
Exhibit 34: Eisai: Product Segmentation by Revenue 2013 and 2014 (US$ million)
Exhibit 35: Eisai: Geographical Segmentation by Revenue 2014
Exhibit 36: GlaxoSmithKline: Business Segmentation 2014
Exhibit 37: GlaxoSmithKline: Business Segmentation by Revenue 2013 and 2014 (US$ billion)
Exhibit 38: GlaxoSmithKline: Sales by Geography 2014
Exhibit 39: GlaxoSmithKline: Pipeline Products 2014
Exhibit 40: Pfizer: Business Segmentation by Revenue 2014
Exhibit 41: Pfizer: Business Segmentation by Revenue 2013 and 2014
Exhibit 42: Pfizer: Geographical Segmentation by Revenue 2014
Exhibit 43: UCB: Product Segmentation by Revenue 2014
Exhibit 44: UCB: Product Segmentation by Revenue 2013 and 2014 (US$ million)
Exhibit 45: UCB: Geographical Segmentation by Revenue 2014



【掲載企業】

Eisai ,GlaxoSmithKline ,Pfizer ,UCB,Abbvie,Acorda Therapeutics,Dainippon Sumitomo Pharma,F. Hoffmann-La Roche,H. Lundbeck,Janssen Pharmaceuticals,Marinus Pharmaceuticals,Meda AB,Novartis,Sage Therapeutics,Shire,Sunovion Pharmaceuticals,Supernus Pharmaceuticals,Upsher-Smith Laboratories,Valeant Pharmaceuticals

【資料のキーワード】

てんかん(Epilepsy)、治療薬、製薬、医薬品

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[アジア太平洋のてんかん(Epilepsy)治療薬市場] (Epilepsy Therapeutics Market in the APAC Region 2015-2019 / IRTNTR4895)販売に関する免責事項
[アジア太平洋のてんかん(Epilepsy)治療薬市場] (Epilepsy Therapeutics Market in the APAC Region 2015-2019 / IRTNTR4895)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆